XORTX 宣布新的临床顾问委员会成员。 XORTX Announces New Clinical Advisory Board Member.

XORTX Therapeutics 是一家专注于治疗常染色体显性多囊肾病 (ADPKD) 的生物制药公司，宣布 Ronald Perrone 博士加入其临床顾问委员会。 XORTX Therapeutics, a biopharmaceutical company focused on treating autosomal dominant polycystic kidney disease (ADPKD), has announced the addition of Dr. Ronald Perrone to its Clinical Advisory Board. Perrone 博士是塔夫茨大学医学院的医学教授，为董事会带来了丰富的医疗和专业经验。 Dr. Perrone, a professor of medicine at Tufts University School of Medicine, brings substantial medical and professional experience to the board. 该公司期望 Perrone 博士在继续开发 ADPKD 创新疗法时做出宝贵贡献。 The company anticipates valuable contributions from Dr. Perrone as they continue to develop innovative therapies for ADPKD.

文章

Benzinga

Street Insider

GlobeNewswire

LeLézard

Business Insider

-- 显示更少 --

延伸阅读